Mouse vas deferens protein (MVDP) is a member of the aldo-keto reductase superfamily. The regulation of MVDP gene expression by activators of the protein kinase A signalling pathway was investigated in human (H295-R) and murine (Y1) adrenocortical carcinoma cells. Immunoblotting with polyclonal antibodies showed that MVDP is expressed in adrenal glands from mouse, rat, rabbit and guinea-pig, probably under the control of ACTH. In both adrenocortical cell lines used, MVDP is constitutively synthesized and its accumulation is increased by treatment with cAMP or forskolin. MVDP mRNA steady-state levels were up-regulated by forskolin in adrenocortical cells by a process that does not require de novo protein synthesis. The results suggest that cAMP is at least one of the key regulators of adrenal MVDP expression and that this effect is direct.
Introduction
Aldo-keto reductases represent a multigene superfamily of monomeric proteins that are widely distributed in man and animals (reviewed by Bhatnagar & Srivastava 1992) . Many subfamilies have been recognized, including aldehyde and aldose reductases, a number of hydroxysteroid dehydrogenases and plant chalcone reductases. The various aldo-keto reductases show broad overlapping substrate specificities for aldehydes and ketones, including xenobiotics as well as endogenous compounds (Bohren et al. 1989) . Recent data concerning methotrexate resistance in Leishmania and cysteine protease inhibitor resistance in Chinese hamster ovary (CHO) cells suggest that members of the aldo-keto reductase superfamily may be used as a detoxifying system (Callahan & Beverley 1992 , Inoue et al. 1993 .
Among the aldo-keto reductase family, aldose reductase is one of the best studied because of its possible role in the development of some diabetic complications such as retinopathy, neuropathy and nephropathy (Kinoshita & Nishimura 1988) . Recently, it has been suggested that the induction of aldose reductase during oxidative stress might represent an important cellular anti-oxidant defence mechanism that could be involved in the pathogenesis of atherosclerosis (Spycher et al. 1997) . Aldose reductase is a ubiquitous 'house keeping' enzyme, probably functional in all cells, that has been isolated and purified from a number of human and animal tissues (Bhatnagar & Srivastava 1992) . For many years, the activity of aldose reductase was assumed to be very low or absent in the mouse (Varma & Kinoshita 1974 ). However, the cloning and sequencing of murine aldose reductase have recently been reported (Daoudal et al. 1995 , Gui et al. 1995 . Interestingly, two aldose reductase-like sequences similar to human and rat aldose reductases have recently been reported in the mouse. Adult mouse vas deferens contains a large amount of a 34·5 kDa protein (mouse vas deferens protein (MVDP)) (Taragnat et al. 1988) . The amino acid sequence of MVDP exhibits a high degree of identity with members of the aldo-keto reductase superfamily, especially aldose reductase from human placenta (71%) and rat lens (69%) (Pailhoux et al. 1990) . It has been shown that testosterone is the signal that triggers MVDP gene expression at the protein and mRNA levels , Taragnat et al. 1990 . Fibroblast growth factor (FGF)-1 can induce the expression of a transcript referred to as FR-1 (Donohue et al. 1994) . The sequence identity between this FR-1 and rat or human aldose reductase is approximately 70%. FR-1 mRNA is detectable in a number of mouse tissues but is most abundant in newborn liver and in adult intestine, ovary and testis (Donohue et al. 1994) . The amino acid sequence identity between FR-1 and MVDP is 82%. Additional proteins with a high degree of sequence identity with MVDP have recently been identified. During hepatocarcinogenesis, the most prominent tumourassociated protein variant (spot 17) revealed a 92% identity with MVDP (Zeindl-Eberhart et al. 1994 ). An inducible aldo-keto reductase from CHO cells shows greatest amino acid sequence identity to mouse FR-1 and MVDP (92 and 80% respectively) (Hyndman et al. 1997) . Although aldose reductases and other members of the aldo-keto reductase family are involved in cellular homeostasis (Bhatnagar & Srivastava 1992) , little is known about the signal transduction pathways that mediate the response of these genes to extracellular signalling molecules. MVDP and FR-1 are unique among the aldo-keto reductase family in that their expression appears to be transcriptionally regulated by androgen (Taragnat et al. 1988 , Fabre et al. 1994 and by growth factors (Donohue et al. 1994) respectively.
High levels of MVDP mRNA were found in the mouse vas deferens but not in that of other species studied, suggesting zoological specificity . Because high levels of MVDP mRNA were recently found in the mouse adrenal (Lau et al. 1995) , the first objective of the current study was to determine if adrenals express MVDP at mRNA and protein levels, and if this expression is restricted to the mouse species. The second objective was to investigate whether cAMP can affect MVDP expression, since this nucleotide is directly involved in the control of glucocorticoid secretion by adrenocorticotrophin (ACTH) (Hanukoglu et al. 1990 ).
Materials and Methods

Cell culture
Murine Y1 adrenocortical tumour cells (Yasumura et al. 1966) were grown in Dulbecco's modified Eagle's-Ham's F-12 medium (DME/F12) supplemented with 10% fetal calf serum, glutamine (2 mM), penicillin (100 units/ml) and streptomycin (100 µg/ml).
Human H295-R adrenocortical carcinoma cells, obtained from the American Type Culture Collection (Rockville, MD, USA), were grown in DME/F12 medium supplemented with 3% fetal calf serum, 2% Ultroser G (Life Technologies Ltd, Paisley, UK), 1% ITS (insulin, transferrin, sodium selenite) (Sigma, St Louis, MO, USA), penicillin (100 units/ml) and streptomycin (100 µg/ml).
Northern blot analysis
Total RNA was extracted from Y1 or H295-R cells with RNAzol (Bioprobe Systems, Montreuil-sous-bois, France), according to the manufacturer's instructions. Twenty or 30 µg of total RNA were electrophoresed in a 1% (w/v) agarose, 2·2 M formaldehyde gel and transferred to nylon filters. The filters were placed for 5 min in u.v. light. The probe used to detect MVDP mRNA was obtained by pGEM-MVDP clone digestion with EcoRI and BamHI, which released MVDP cDNA (1·2 kb). The cDNAs were labelled with [ 32 P]dCTP using the Megaprime DNA Labelling System (Amersham France SA, Les Ulis, France). Prehybridization was done for 1·5 h at 65 C in a solution containing 3 SSC, polyvinylpyrrolidone (0·2%), ficoll (0·2%), polyethylene glycol (5%), glycine (1%), SDS (1%) and 100 µg/ml denatured salmon sperm DNA. Hybridization was performed overnight at 65 C in the same solution containing 1 10 6 c.p.m./ml of 32 P-labelled MVDP cDNA probes. Filters were washed at 65 C. To verify the relative quantities of MVDP mRNA, Northern blots were stripped and rehybridized in the same buffer described above, at 65 C with a 32 P-labelled 18S rRNA cDNA provided by N Ghyselinck (LGME, INSERM U184, Strasbourg, France) or a 32 P-labelled poly A binding protein (PABP) cDNA (Grange et al. 1987) . Autoradiography was carried out by exposing the blots to XAR-S films (Kodak) for 48 h with an intensifying screen at 80 C. The maximum induction factors of MVDP mRNA concentrations under forskolin treatment were quantified by densitometric scanning of the Northern blots X-ray film using specially developed software (Grafteck, Aix en Provence, France) on an Apple MacIntosh computer. The mean values (from three to five independent experiments) have been calculated between 1 and 3 h (Y1 cells) or between 1 and 6 h (H295-R cells) of forskolin treatment.
Western blot analysis
Frozen individual tissue samples were homogenized in 100-300 µl 250 mM Tris-HCl (pH 7·5), 0·4 mM PMSF using a glass-glass tissue homogenizer and centrifuged in a microfuge at 10 000 g at 4 C for 15 min. For Western blot analysis of MVDP content of cells, a fraction of cell sample was collected before RNAzol extraction. The concentration of soluble proteins was determined by the Bradford method (Bio-Rad Laboratories GmbH, Munich, Germany). Soluble tissue or cellular extracts (10-20 µg protein) were subjected to SDS-PAGE on 10% acrylamide gels and transferred to nitrocellulose membranes in a Bio-Rad apparatus according to the manufacturer's instructions. To block non-specific protein binding sites the nitrocellulose was incubated for 1 h at room temperature in TBST (50 mM Tris-HCl (pH 8), 150 mM NaCl, 0·1% (v/v) Tween 20) containing 5% (w/v) nonfat dried milk and the incubation with the primary monoclonal or polyclonal antibody was for 1 h at room temperature as previously described , Taragnat et al. 1990 . Following three washes in TBST, the sheets were incubated for 1 h at room temperature with the second antibody (peroxidase-conjugated antirabbit IgG (Boehringer Mannheim GmbH, Germany) diluted 1:15 000. The blots were washed again, and peroxidase activity was detected by autoradiography with the ECL enhanced chemiluminescence system (Amersham).
Immunocytochemistry
Immediately after killing, vas deferens and adrenals were fixed in 75% ethanol, 25% acetic acid for 30 min, dehydrated in absolute ethanol and embedded in paraffin wax. After dewaxing, slides containing sections of 6 µm were incubated overnight at 4 C with primary antibody diluted 1:80 in PBS containing 5% (w/v) non-fat dried milk (Martinez et al. 1989) . Slides were then rinsed three times in PBS and treated for 2 h at room temperature with anti-rabbit-peroxidase antibody diluted 1:400. Peroxidase activity was revealed using standard immunoperoxidase procedures (Carlson et al. 1988) . Control slides were obtained by incubation of tissue sections with nonimmune serum.
Plasmid constructs
All plasmid constructs were prepared using standard methods (Sambrook et al. 1989) . The mouse mammary tumour virus-chloramphenicol acetyl transferase (MMTV-CAT) vector contains the upstream sequence of the long terminal repeat promoter of the MMTV in front of the CAT reporter gene. The pSV-ARo vector contains an SV40 promoter directing the transcription of the full-length human androgen receptor cDNA (Brinkmann et al. 1989) .
Transient transfections and CAT assays
One day before transfection, Y1 cells were plated at a density of 10 6 cells/60 mm dish. Two hours prior to addition of the calcium phosphate/DNA precipitates, the medium was replaced with Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Transfection was performed by the calcium phosphate method (Chen & Okayama 1987 ) using 2 µg MMTV-CAT and 1·5 µg pSV-ARo vectors. The medium was changed the morning after transfection, and the cells were maintained in the presence or absence of 10 6 M 5 -dihydrotestosterone (DHT) for 48 h.
CAT activity of cell extracts was assayed according to the method of Neumann et al. (1987) .
Samples of proteins (20 µl) were incubated in 80 µl 250 mM Tris-HCl (pH 7·8), 0·2 mM acetyl coenzyme A, 0·12 µCi of [ 14 C]chloramphenicol for 3 h at 37 C. After thin layer chromatography and autoradiography, acetylated and non-acetylated forms were excised and quantified by scintillation counting. CAT activity corresponds to the ratio of acetylated-form radioactivity to total radioactivity (both forms).
Animals
Mice of the Swiss strain (CD-1; Charles River, Saint Aubin les Elbeuf, France) were used. To investigate the role of pituitary ACTH, adult males were treated with corticosterone (75 µg dissolved in sesame oil were injected s.c. every day) for 7 days and killed 6 h after the last injection. Tissues (vasa deferentia and adrenals) were removed, frozen in liquid nitrogen and stored at 70 C until Western blot analysis.
Results
Expression of MVDP in adrenal glands
High levels of MVDP mRNA have been found in the mouse adrenal gland (Lau et al. 1995) . By Western blot analysis using the monoclonal antibody against MVDP, antigens corresponding to this protein could be detected in adrenal glands from mouse and rat (Fig. 1A) . By immunoblotting, a cross-reaction was found between the anti-MVDP polyclonal antibody and proteins from adrenal glands of rat, rabbit and guinea-pig (Fig. 1B) . Although not quantified, the amount of MVDP in the adrenals was higher than that in vas deferens, except in mouse. As shown with recombinant proteins, the polyclonal and monoclonal antibodies used do not cross-react with aldose reductase.
Immunohistochemical staining was performed to localize the protein in histological sections of the adrenal gland. Figure 2A shows that there is a strong staining in the cortex but not in the medulla, and that the reactivity seems to be restricted to the zona fasciculata. The staining reaction can be abolished by preabsorbing the primary Figure 1 Western blot analysis of 20 µg protein from vas deferens (vd) and adrenal glands (adr) from mouse, rat, rabbit and guinea-pig and 10 µg recombinant murine aldose reductase (AR) and MVDP. After SDS-PAGE, the proteins were transferred to nitrocellulose and incubated with (A) monoclonal (1:700) or (B) polyclonal (1:3000) antibody specific for MVDP.
antibody with antigen and no staining was observed when tissue sections were incubated with non-immune serum (Fig. 2B) .
Androgens do not activate MVDP expression in cultured adrenocortical cells
To avoid the limitations inherent in whole animal studies, we have used adrenocortical tumour cells of mouse origin (clone Y1), and human H295-R adrenocortical carcinoma cells. Expression of MVDP and its mRNA is dependent on the androgen status of animals (Taragnat et al. 1988 ) and vas deferens epithelial cell cultures express MVDP in response to androgens (Manin et al. 1992) . To test whether MVDP expression in adrenals is influenced by androgens, adrenocortical cells were cultured in the presence of DHT or the synthetic androgen R1881.
Total RNA was extracted from cultured cells and the RNA blot was hybridized with the MVDP cDNA labelled with 32 P. In Y1 cell lines the probe was found to hybridize a single band (Fig. 3) , the approximate size of which (1·4 kb) is similar to the MVDP mRNA found in vas deferens. When DHT or R1881 was present during 24 h, the level of MVDP mRNA was not significantly affected in Y1 cells. Similar results were obtained using H295-R cells (not shown).
MMTV-CAT was used to test the presence of functional androgen receptors in adrenocortical cells, since it is well known that the hormone response elements of MMTV are activated by a variety of steroids in different cell lines (Parker et al. 1987) . As shown in Fig. 4 , MMTV-CAT does not respond to 10 6 M DHT, suggesting that Y1 adrenocortical cells lack androgen receptors. After cotransfection of the androgen receptor expression vector (pSV-ARo), significant induction of CAT activity was observed with extract from cells stimulated by 10 6 M DHT. Similar observations were made after cotransfection of the progesterone receptor expression vector and stimulation by progesterone or R1881 (not shown). 
Activation of the protein kinase A (PKA) signalling pathway increases MVDP and MVDP mRNA levels in adrenocortical cells
In the adrenal gland, steroidogenesis is stimulated by ACTH through elevation of cAMP and the subsequent activation of cAMP-dependent PKA (Hanukoglu et al. 1990) . To examine possible regulation of MVDP expression by the PKA transduction pathway, Y1 adrenocortical cells were cultured in the presence of db-cAMP or steroids. As shown in Fig. 5 , treatment of cells for 36 h with 1 mM db-cAMP resulted in an increase in the expression of MVDP. The ability of db-cAMP to induce MVDP expression was not shared by R1881, progesterone, dexamethasone, aldosterone or oestradiol, indicating that this induction is independent of the steroidogenesis stimulation.
To determine the time course of MVDP induction, cultured Y1 and H295-R cells were treated with 10 5 M forskolin, an activator of cAMP synthesis in cells, for increasing periods of time. On the basis of Western blot analysis of cell extracts, MVDP was expressed at very low levels at 6 h, and increased about 37-fold until 19 h in Y1 cells (Fig. 6A) . In H295-R cells, MVDP induction occurred 12 h after forskolin addition and varied little until 24 h (Fig. 6b) .
To assess if these increases in MVDP immunoreactivity were potentially transcriptionally regulated, steady-state levels of MVDP mRNA were examined following PKA activation. Treatment of cells with 10 5 M forskolin for 2 h (Y1 cells) or 1 h (H295-R cells) led to expression of MVDP mRNA. The stimulating effect of forskolin is time dependent and induction is about 10-fold after 3 h (Y1 cells) or 9-fold after 6 h (H295-R cells) compared with levels determined after 1 h induction (Fig. 6c,d ). The accumulation of MVDP and of its mRNA had a closely related developmental pattern. However, whereas the induction of MVDP mRNA was maximal 3 h (Y1 cells) or 6 h (H295-R cells) after forskolin addition, the maximal MVDP levels were detected only at 19 h (Y1 cells) or 24 h (H295-R cells). This lag period probably corresponds to the translation of the mRNA accumulated at 3 h (Y1 cells) or 6 h (H295-R cells).
Treatment of Y1 cells for 36 h with 10 6 M ACTH had no significant effect on MVDP mRNA levels (not shown).
To determine whether cAMP exerts its action through newly synthesized proteins, the effect of cycloheximide, a protein synthesis inhibitor (which blocks the peptidyl transferase reaction on ribosomes in eukaryotes), on MVDP mRNA levels was examined. Y1 and H295-R cells were treated for 6 h and 24 h with 2·8 µg/ml cycloheximide alone or in combination with forskolin. As shown in Fig. 6c,d , when cycloheximide was given in concert with forskolin, the stimulatory effect of the activator on MVDP mRNA levels was unchanged in Y1 or even strengthened in 24 h treated H295-R cells. Western blot analysis showed that this treatment abolished the increase in MVDP levels induced by forskolin, indicating that the dose of cycloheximide used is sufficient to inhibit protein synthesis (Fig. 6a,b) .
Hormonal regulation of MVDP in adrenal glands
To determine whether MVDP expression in adrenals might be induced by cAMP, we studied the effects of exogenous glucocorticoids which have a direct negative feedback effect on pituitary ACTH secretion. As shown in Fig. 7 , corticosterone treatment for 7 days strongly reduced MVDP expression in adrenals but not in the vas deferens from adult males.
Discussion
It has been recently shown that the expression of MVDP is not restricted to the vas deferens, since high levels of Figure 4 Search for functional androgen receptors in Y1 cells. Cells were seeded at a density of 10 6 per 60 mm plastic dish and transfected 24 h later with 2 µg MMTV-CAT vector and cotransfected with 1·5 µg pSV-ARo vector using the calcium phosphate method (Chen & Okayama 1987) . The medium was changed the morning after transfection, and the cells were maintained in the presence or absence of 10 6 M DHT for 48 h. Autoradiogram of CAT gene expression.
Figure 5 Expression of MVDP in murine adrenocortical cells (Y1).
Western blot analysis of 20 µg protein from vas deferens (vd) and adrenal glands (adr) from mouse and cells cultured (a) in basal serum-free medium or with (b) 1 mM db-cAMP, (c) 10 7 M R1881, (d) 10 6 M progesterone, (e) 10 6 M dexamethasone, (f) 10 6 M aldosterone, (g) 10 6 M oestradiol for 36 h. After SDS-PAGE, the proteins were transferred to nitrocellulose and incubated with monoclonal antibody specific for MVDP (1:700).
MVDP mRNA were found in the adrenal glands, whereas low levels were detected in several tissues including eye, intestine, seminal vesicle, kidney, liver, testis and lung (Lau et al. 1995) . We report here that, using a specific polyclonal antibody, MVDP is present in large amounts in mouse, rat, rabbit and guinea-pig adrenal glands. MVDP mRNA and protein were also detected in the two cell lines used in these studies: the murine Y1 adrenocortical tumour cell line, and the human H295-R adrenocortical carcinoma cells. Thus it appears that the expression of MVDP in the adrenal glands is not specific for the mouse.
The structural zonation of the adrenal cortex roughly correlates with the biosynthesis of different steroids. In the mature gland, the zona glomerulosa synthesizes mineralocorticoids, whereas fasciculata, and less importantly the reticularis, synthesize glucocorticoids and androgens. MVDP was localized in the zona fasciculata, suggesting that this protein may be involved in the metabolism of adrenal steroids. It has been shown recently that degradation of steroids by reduction of their aldehyde and ketone groups may result primarily, not from specific dehydrogenases, but from the broad specificity of enzymes of the aldo-keto reductase superfamily (Stolz et al. 1991 , Warren et al. 1993 . Recently, it has been shown that aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands (Matsuura et al. 1996) . Hence, the homology of MVDP with some hydroxysteroid dehydrogenases may offer a clue to its function in adrenals. The enzymatic nature of MVDP has not yet been demonstrated. However, the degree of homology to aldose reductases, and the conservation of amino acid residues known for their importance in NADPH binding and catalytic activity, suggest that MVDP has NADPHdependent reductase activity (Daoudal et al. 1995) . There is a great variability in tissue MVDP levels and the expression of the MVDP gene is regulated by different 
Figure 7
Hormonal regulation of MVDP in adrenal glands. Adult male mice were treated with corticosterone for 7 days and killed 6 h after the last injection. Western blot analysis of 10 µg protein from vas deferens and adrenal glands. After SDS-PAGE, the proteins were transferred to nitrocellulose and incubated with monoclonal antibody specific for MVDP (1:700).
factors (see below). These observations suggest that MVDP can be involved in more specific physiological roles in tissues which contain high levels of the protein, i.e. vas deferens and adrenals.
Little is known about the factors which can regulate the expression level of aldo-keto reductase family genes. Regulation by hypertonicity is now well established for the human, rabbit, and mouse aldose reductase genes, and tonicity-responsive elements have been identified in the promoters (Ferraris et al. 1994 , Daoudal et al. 1997 , Ko et al. 1997 . The FR-1 gene is induced by growth factors such as FGF, epidermal growth factor and platelet-derived growth factor, and by phorbol esters (Donohue et al. 1994) . Similarly, expression of aldose reductase in astrocytes is due to the effects of FGF ( Jacquin-Becker & Labourdette 1997). The expression of the aldose reductase gene in the ovary seems to be regulated by gonadotrophic hormones (Iwata et al. 1996) . Although androgens are hormonal regulators of MVDP in the vas deferens (Taragnat et al. 1988 , the mechanisms controlling expression of this gene in other tissues remain unknown. ACTH regulates the synthesis and release of various adrenal steroid hormones, especially those of glucocorticoids. In adrenocortical cells, the hormonal induction is mediated predominantly by increases in intracellular cAMP and subsequent activation of the PKA signalling pathway (Hanukoglu et al. 1990) . In this report we show that, in murine and human adrenocortical cells, the MVDP gene is induced by cAMP at mRNA and protein levels. The time course of the induction demonstrates that this is indeed a relatively early transcriptional response of adrenocortical cells to cAMP. The transcripts of the MVDP gene were first detected after 2 h of forskolin treatment and were fully induced within 3 h (Y1 cells). MVDP mRNA levels do not increase in magnitude with longer exposure. Our results suggest that Y1 cell lines used in these experiments lack androgen receptor. Thus activation of MVDP gene expression by cAMP in cultured adrenocortical Y1 cells cannot be due to the steroidogenic effects of this nucleotide. Our preliminary in vivo studies suggest that in adrenals MVDP expression is stimulated by ACTH. The effects of ACTH on steroidogenesis can be divided into acute effects, which occur within minutes, and chronic effects, which require hours or days (Simpson & Waterman 1988) . The acute effect of ACTH is to increase mobilization and delivery of cholesterol to the mitochondrial inner membrane, where it is converted to pregnenolone by the side-chain cleavage enzyme P450 scc ( Jefcoate et al. 1987) . In contrast, the chronic effects of ACTH result from increased transcription of the steroidogenic genes and general trophic actions on adrenocortical cells (Simpson & Waterman 1988) . The MVDP gene showed a significant lag period (2 h in Y1 cells) between the time forskolin was added to the medium and when MVDP mRNA levels began to rise significantly. Thus the time course of MVDP induction by forskolin is similar to the delayed induction described for cAMPinduced steroidogenic genes in adrenals ( John et al. 1986 ). However, cycloheximide experiments suggest that cAMP induction of the MVDP gene is direct and does not require the presence of newly synthesized labile proteins. In contrast, induction of steroidogenic enzymes by cAMP is sensitive to cycloheximide treatment, leading to the proposal that cAMP induces steroidogenic gene expression by an indirect mechanism (Bokar et al. 1988) . Recently, it has been suggested that transcription factors such as steroidogenic factor 1 (SF-1) and SV40-specific factor 1 (Sp1) may act as mediators of cAMP-induced P450 scc gene expression (Liu & Simpson 1997) . Interestingly, the promoter region of the MVDP gene contains two sequences homologous with cAMP response element (positions 1746 and 1019) and potential recognition sequences for the SF-1 and Sp1 factors (positions 453 and 44 respectively).
Activation of the MVDP gene by androgens in vas deferens epithelial cells is sensitive to cycloheximide, indicating a need for de novo protein synthesis (Dassouli et al. 1994) . Thus the stimulation of the MVDP gene is regulated by different pathways depending on cell type. Further functional characterization of the MVDP promoter region will help to elucidate the role of putative trans-acting factors in the control of MVDP gene expression.
